These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 16870037)

  • 41. Estimating the economic and social costs of dementia in Ireland.
    Connolly S; Gillespie P; O'Shea E; Cahill S; Pierce M
    Dementia (London); 2014 Jan; 13(1):5-22. PubMed ID: 24381036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimating the potential cost savings from the New York University Caregiver Intervention in Minnesota.
    Long KH; Moriarty JP; Mittelman MS; Foldes SS
    Health Aff (Millwood); 2014 Apr; 33(4):596-604. PubMed ID: 24711320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Associated Factors of Total Costs of Alzheimer's Disease: A Cluster-Randomized Observational Study in China.
    Yan X; Li F; Chen S; Jia J
    J Alzheimers Dis; 2019; 69(3):795-806. PubMed ID: 31156170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Care arrangements for people with dementia in developing countries.
    Prince M;
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):170-7. PubMed ID: 14758582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost of Alzheimer's disease in a developing country setting.
    Zencir M; Kuzu N; Beşer NG; Ergin A; Catak B; Sahiner T
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):616-22. PubMed ID: 16021668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychiatric profiles of patients with Alzheimer's disease and vascular dementia in Taiwan.
    Hsieh CJ; Chang CC; Lin CC
    Int J Geriatr Psychiatry; 2009 Jun; 24(6):570-7. PubMed ID: 19051223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
    J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The economic costs of dementia in Korea, 2002.
    Suh GH; Knapp M; Kang CJ
    Int J Geriatr Psychiatry; 2006 Aug; 21(8):722-8. PubMed ID: 16858741
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan.
    Ashizawa T; Igarashi A; Sakata Y; Azuma M; Fujimoto K; Kobayashi T; Takase Y; Ikeda S
    J Alzheimers Dis; 2021; 81(1):367-374. PubMed ID: 33780368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consequences of Anosognosia on the Cost of Caregivers' Care in Alzheimer's Disease.
    Turró-Garriga O; Garre-Olmo J; Reñé-Ramírez R; Calvó-Perxas L; Gascón-Bayarri J; Conde-Sala JL
    J Alzheimers Dis; 2016 Oct; 54(4):1551-1560. PubMed ID: 27636844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
    Gustavsson A; Cattelin F; Jönsson L
    Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dependence in Alzheimer's disease and service use costs, quality of life, and caregiver burden: the DADE study.
    Jones RW; Romeo R; Trigg R; Knapp M; Sato A; King D; Niecko T; Lacey L;
    Alzheimers Dement; 2015 Mar; 11(3):280-90. PubMed ID: 25074342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries.
    Afram B; Stephan A; Verbeek H; Bleijlevens MH; Suhonen R; Sutcliffe C; Raamat K; Cabrera E; Soto ME; Hallberg IR; Meyer G; Hamers JP;
    J Am Med Dir Assoc; 2014 Feb; 15(2):108-16. PubMed ID: 24238605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Caregiver burden in atypical dementias: comparing frontotemporal dementia, Creutzfeldt-Jakob disease, and Alzheimer's disease.
    Uflacker A; Edmondson MC; Onyike CU; Appleby BS
    Int Psychogeriatr; 2016 Feb; 28(2):269-73. PubMed ID: 26435062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Caregiver burden in dementia: evaluation with a Japanese version of the Zarit caregiver burden interview].
    Hirono N; Kobayashi H; Mori E
    No To Shinkei; 1998 Jun; 50(6):561-7. PubMed ID: 9656252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cost of Alzheimer's disease in China and re-estimation of costs worldwide.
    Jia J; Wei C; Chen S; Li F; Tang Y; Qin W; Zhao L; Jin H; Xu H; Wang F; Zhou A; Zuo X; Wu L; Han Y; Han Y; Huang L; Wang Q; Li D; Chu C; Shi L; Gong M; Du Y; Zhang J; Zhang J; Zhou C; Lv J; Lv Y; Xie H; Ji Y; Li F; Yu E; Luo B; Wang Y; Yang S; Qu Q; Guo Q; Liang F; Zhang J; Tan L; Shen L; Zhang K; Zhang J; Peng D; Tang M; Lv P; Fang B; Chu L; Jia L; Gauthier S
    Alzheimers Dement; 2018 Apr; 14(4):483-491. PubMed ID: 29433981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias.
    Hill J; Fillit H; Thomas SK; Chang S
    Pharmacoeconomics; 2006; 24(3):265-80. PubMed ID: 16519548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.